Which antibiotic is effective as a single-dose therapy for trachoma?
Which agent is used for pupillary dilatation in children?
Which antiglaucoma drug is contraindicated in sulfonamide hypersensitivity?
Which of the following drugs is contraindicated in a patient with glaucoma who also has bronchial asthma?
Which prostaglandin is used in the management of glaucoma?
Which drug should be avoided in a patient with angle closure glaucoma?
Which drug is known to cause bull's eye maculopathy?
Which local anesthetic is specifically used to produce corneal anesthesia for tonometry?
Agonistic action at which of the following adrenergic receptors results in the reduction of aqueous humor secretion?
What is the topical antifungal of choice for keratomycosis?
Explanation: **Explanation:** **Azithromycin (Option C)** is the drug of choice for the treatment of trachoma caused by *Chlamydia trachomatis*. Its effectiveness as a **single-dose therapy (20 mg/kg up to 1 gram)** is due to its unique pharmacokinetic profile: it has an exceptionally long tissue half-life (approximately 68 hours) and excellent intracellular penetration. This allows a single oral dose to maintain therapeutic concentrations in the conjunctival tissues for up to 7–14 days, ensuring high patient compliance compared to multi-day regimens. **Why other options are incorrect:** * **Doxycycline (Option A):** While effective against Chlamydia, it requires a prolonged course (100 mg twice daily for 7–14 days). It is contraindicated in children under 8 years and pregnant women. * **Erythromycin (Option B & D):** These macrolides are effective but require multiple doses over several days (e.g., 500 mg twice daily for 14 days). They are typically reserved for infants or pregnant women where Azithromycin is unavailable, but they are not single-dose treatments. **High-Yield Clinical Pearls for NEET-PG:** * **SAFE Strategy (WHO):** **S**urgery (for trichiasis), **A**ntibiotics (Azithromycin), **F**acial cleanliness, and **E**nvironmental improvement. * **Mass Drug Administration (MDA):** If the prevalence of active trachoma (TF) in children aged 1–9 years is **>5%**, the entire community should receive annual antibiotic treatment. * **Topical Treatment:** 1% Tetracycline eye ointment (twice daily for 6 weeks) is an alternative but has poor compliance compared to oral Azithromycin. * **Trachoma Inclusion Bodies:** Known as **Halberstaedter-Prowazek (HP) bodies**, found in the cytoplasm of conjunctival epithelial cells.
Explanation: **Explanation:** The correct answer is **Atropine (Option A)**. In pediatric ophthalmology, the primary goal for pupillary dilatation is often to perform an accurate **cycloplegic refraction**. Children have a very strong accommodative reflex due to a highly active ciliary muscle. Atropine is the most potent cycloplegic and mydriatic agent available. It effectively paralyzes the ciliary muscle (cycloplegia) and dilates the pupil (mydriasis), allowing for the measurement of the full refractive error, especially in cases of accommodative esotropia and pediatric strabismus. **Analysis of Options:** * **Homatropine (Option B):** It is a semi-synthetic alkaloid with moderate potency. While used for cycloplegia, its effect is weaker than Atropine and is more commonly used in treating anterior uveitis to prevent synechiae. * **Tropicamide (Option C):** It has the fastest onset and shortest duration of action. It is the drug of choice for routine fundus examination in **adults**, but its cycloplegic effect is insufficient to overcome the strong accommodation in children. * **Phenylephrine (Option D):** This is a sympathomimetic alpha-1 agonist. It causes mydriasis without cycloplegia. It is often used as an adjunct to tropicamide but is never used alone for refraction in children. **High-Yield NEET-PG Pearls:** * **Drug of Choice (DOC):** Atropine (1% ointment or drops) is the DOC for refraction in children **<7 years** of age. * **Cyclopentolate:** The DOC for children **7–24 years** of age. * **Atropine Toxicity:** Watch for "Red as a beet, Dry as a bone, Blind as a bat, Mad as a hatter." In children, use ointment to prevent systemic absorption via the nasolacrimal duct. * **Duration:** Atropine effects can last up to 7–10 days.
Explanation: **Explanation:** **Acetazolamide** is a potent systemic **Carbonic Anhydrase Inhibitor (CAI)**. Chemically, it is a non-bacteriostatic **sulfonamide derivative**. Because it shares a similar chemical structure (the sulfonamide group) with sulfa antibiotics, there is a significant risk of cross-reactivity. In patients with sulfonamide hypersensitivity, administration of Acetazolamide can trigger severe allergic reactions, ranging from skin rashes to life-threatening conditions like Stevens-Johnson Syndrome (SJS) or Toxic Epidermal Necrolysis (TEN). **Why other options are incorrect:** * **Beta-blockers (e.g., Timolol):** These are adrenergic antagonists. Their primary contraindications are respiratory (Asthma, COPD) and cardiac (Bradycardia, Heart block), not sulfa allergies. * **Pilocarpine:** This is a cholinergic agonist (miotic). It is contraindicated in patients with uveitis or high risk of retinal detachment. * **Prostaglandin analogues (e.g., Latanoprost):** These are lipid compounds. They are generally avoided in active intraocular inflammation (uveitis) or cystoid macular edema. **High-Yield Clinical Pearls for NEET-PG:** * **Topical CAIs:** Drugs like **Dorzolamide** and **Brinzolamide** are also sulfonamide derivatives and should be used with caution in sulfa-allergic patients. * **Side Effects of Acetazolamide:** Metabolic acidosis, hypokalemia, renal stones, and paresthesia (tingling in extremities). * **Mechanism:** CAIs reduce aqueous humor production by inhibiting the enzyme carbonic anhydrase in the ciliary body epithelium. * **Drug of Choice:** Acetazolamide is the drug of choice for the rapid reduction of intraocular pressure in **Acute Angle Closure Glaucoma**.
Explanation: **Explanation:** **Timolol maleate** is a non-selective beta-blocker (blocking both $\beta_1$ and $\beta_2$ receptors). While it effectively reduces intraocular pressure by decreasing aqueous humor production, its systemic absorption through the nasolacrimal duct can lead to significant side effects. Blocking $\beta_2$ receptors in the lungs causes **bronchoconstriction**, which can precipitate a life-threatening asthma attack. Therefore, it is strictly contraindicated in patients with bronchial asthma or severe COPD. **Analysis of Incorrect Options:** * **Latanoprost:** A Prostaglandin F2$\alpha$ analogue. It is the first-line drug for primary open-angle glaucoma and has no significant effect on the respiratory system. * **Betaxolol:** A **cardioselective ($\beta_1$) blocker**. While it is safer than Timolol because it has less affinity for $\beta_2$ receptors in the lungs, it is still used with caution. However, in the context of this question, Timolol is the "most" contraindicated due to its non-selective nature. * **Brimonidine:** An $\alpha_2$ agonist. It reduces aqueous production and increases uveoscleral outflow. Its main contraindication is in infants (due to CNS depression/apnea) and patients on MAO inhibitors, not asthma. **Clinical Pearls for NEET-PG:** * **Nasolacrimal Occlusion (NLO):** Instructing patients to apply pressure over the lacrimal sac for 2-3 minutes after instillation reduces systemic absorption of Timolol. * **Drug of Choice (DOC):** Latanoprost is the DOC for most glaucomas; Timolol was the previous gold standard. * **Side Effects:** Watch for **bradycardia** and heart block with Timolol. For Latanoprost, watch for **iris heterochromia** (darkening) and hypertrichosis of eyelashes.
Explanation: **Explanation:** Prostaglandin analogues (PGAs) are currently the **first-line medical therapy** for Primary Open Angle Glaucoma (POAG) and Ocular Hypertension. They work primarily by increasing the **uveoscleral outflow** of aqueous humor (and to a lesser extent, trabecular outflow) by remodeling the extracellular matrix in the ciliary muscle. **Analysis of Options:** * **Latanoprost (0.005%):** A selective FP receptor agonist. It was the first PGA introduced and remains a gold standard for efficacy and safety. * **Travoprost (0.004%):** A full agonist at the FP receptor, showing similar efficacy to Latanoprost. * **Bimatoprost (0.03%):** Technically a synthetic prostamide. It is often considered the most potent in this class for lowering Intraocular Pressure (IOP) but may have a higher incidence of conjunctival hyperemia. Since all three agents are FDA-approved and standard clinical choices for glaucoma management, **Option D (All of the above)** is the correct answer. **High-Yield Clinical Pearls for NEET-PG:** * **Mechanism:** Increase uveoscleral outflow (High-yield: "U" for Prostaglandins, "T" for Beta-blockers/Trabecular). * **Dosage:** Once-daily (HS - at bedtime) dosing improves patient compliance. * **Side Effects:** * **Iris heterochromia** (permanent darkening of the iris due to increased melanin). * **Hypertrichosis** (increased eyelash growth; Bimatoprost is also used for eyelash hypotrichosis). * **Prostaglandin-associated periorbitopathy** (fat loss around eyes). * **Cystoid Macular Edema (CME):** Use with caution in aphakic or pseudophakic patients. * **Contraindication:** Active uveitis (pro-inflammatory nature).
Explanation: **Explanation:** **Why Atropine is the Correct Answer:** Atropine is a potent **parasympatholytic (anticholinergic)** agent that causes **mydriasis** (dilation of the pupil). In patients with narrow angles, mydriasis leads to the bunching up of the peripheral iris tissue towards the drainage angle. This further obstructs the trabecular meshwork, severely impeding the outflow of aqueous humor. Consequently, it can precipitate or worsen an attack of **Acute Angle Closure Glaucoma (AACG)**. Therefore, mydriatics are strictly contraindicated in eyes with narrow angles. **Analysis of Incorrect Options:** * **Acetazolamide (Option A):** A Carbonic Anhydrase Inhibitor that reduces aqueous production. It is a first-line systemic drug used to rapidly lower Intraocular Pressure (IOP) during an acute attack. * **Timolol (Option C):** A topical Beta-blocker that decreases aqueous humor secretion by the ciliary body. It is a standard treatment for managing various types of glaucoma, including angle closure. * **Mannitol (Option D):** An intravenous hyperosmotic agent. It creates an osmotic gradient that draws fluid out of the vitreous into the bloodstream, rapidly reducing IOP in emergency AACG scenarios. **High-Yield Clinical Pearls for NEET-PG:** * **Drug of Choice for AACG:** IV Mannitol or Acetazolamide (to lower IOP) followed by **Pilocarpine** (miotic) once IOP is <30 mmHg. * **Definitive Treatment:** Peripheral Iridotomy (usually via YAG Laser). * **Mydriatic Danger:** Always perform a torch light or slit-lamp examination (Van Herick technique) to assess angle depth before instilling mydriatics like Atropine or Tropicamide. * **Paradoxical Effect:** While Pilocarpine (miotic) is used in AACG, very high concentrations can occasionally worsen the condition by increasing pupillary block.
Explanation: **Explanation:** **Chloroquine** (and its derivative Hydroxychloroquine) is the classic cause of **Bull’s Eye Maculopathy**. These drugs have a high affinity for melanin and bind to the **Retinal Pigment Epithelium (RPE)**. Chronic accumulation leads to RPE atrophy in a concentric ring around the fovea, sparing the central foveal area initially. This creates the characteristic "bull's eye" appearance on fundoscopy. It is a dose-dependent toxicity; the risk increases significantly when the cumulative dose of Chloroquine exceeds 460g or Hydroxychloroquine exceeds 5mg/kg/day. **Analysis of Incorrect Options:** * **Phenytoin:** Primarily associated with neuro-ophthalmic side effects such as **nystagmus** (most common), diplopia, and ophthalmoplegia, rather than maculopathy. * **Steroids:** The hallmark ocular side effects of systemic or topical steroids are **Posterior Subcapsular Cataract (PSC)** and **Secondary Open Angle Glaucoma** (due to increased resistance to aqueous outflow). * **Ethambutol:** This antitubercular drug is notorious for causing **Retrobulbar Neuritis**. It typically presents with a decrease in visual acuity and **red-green color blindness**, not a bull's eye macular pattern. **High-Yield Clinical Pearls for NEET-PG:** * **Early Screening:** The earliest sign of toxicity is a **paracentral scotoma** (detected via Humphrey Visual Field 10-2). * **Diagnosis:** **Optical Coherence Tomography (OCT)** shows the "Flying Saucer sign" (loss of outer retinal layers). **Fundus Autofluorescence (FAF)** is also highly sensitive. * **Other causes of Bull's Eye Maculopathy:** Stargardt’s disease, Cone-Dystrophy, and Benign Concentric Macular Dystrophy. * **Management:** Toxicity is irreversible; the drug must be discontinued immediately upon detection of early changes.
Explanation: **Explanation:** **Benoxinate (Oxybuprocaine)** is the drug of choice for corneal anesthesia during tonometry (specifically Goldmann Applanation Tonometry) because it provides rapid onset (within 30 seconds) and a brief duration of action. Crucially, it is highly compatible with **Fluorescein sodium**, often available in a premixed formulation (Fluress). Unlike other agents, it causes minimal stinging and has a lower risk of causing significant corneal epithelial toxicity or "pitting," which could interfere with accurate intraocular pressure (IOP) readings. **Analysis of Incorrect Options:** * **Tetracaine (Amethocaine):** While commonly used for minor ocular procedures and foreign body removal, it causes significant stinging/burning on instillation and is more toxic to the corneal epithelium compared to Benoxinate. * **Ropivacaine:** This is a long-acting amide anesthetic used primarily for regional anesthesia (e.g., peribulbar or retrobulbar blocks) in ocular surgeries, not for topical surface anesthesia. * **Oxethazaine:** This is a potent mucosal anesthetic used primarily in antacid suspensions for symptomatic relief of gastritis; it has no role in ophthalmic practice. **High-Yield Clinical Pearls for NEET-PG:** * **Proparacaine:** Another common topical anesthetic; it is preferred for pediatric patients because it causes the least amount of initial stinging. * **Mechanism:** Local anesthetics work by blocking **voltage-gated sodium channels**, preventing nerve depolarization. * **Warning:** Topical anesthetics should **never** be prescribed for home use or chronic pain relief, as they inhibit corneal healing and can lead to "Anesthetic Keratopathy" (permanent corneal melting and perforation). * **Preservative:** Most topical drops contain **Benzalkonium chloride (BAK)**, which can enhance drug penetration but may cause ocular surface irritation.
Explanation: **Explanation:** The production and drainage of aqueous humor are regulated by the autonomic nervous system. To reduce intraocular pressure (IOP), pharmacological agents must either decrease secretion from the ciliary body or increase outflow through the trabecular or uveoscleral pathways. **Why Alpha-2 Agonists are Correct:** Alpha-2 ($\alpha_2$) receptors are primarily inhibitory G-protein coupled receptors ($G_i$). Agonism at these receptors on the ciliary epithelium leads to a decrease in intracellular cyclic AMP (cAMP). This reduction in cAMP inhibits the activity of the ciliary processes, thereby **decreasing aqueous humor secretion**. Additionally, some $\alpha_2$ agonists (like Brimonidine) also enhance uveoscleral outflow. **Analysis of Incorrect Options:** * **Beta-1 and Beta-2 receptors:** Stimulation of $\beta$-receptors (primarily $\beta_2$) in the ciliary body **increases** cAMP, which **promotes** aqueous secretion. This is why Beta-blockers (e.g., Timolol) are used to treat glaucoma—they block this stimulatory effect to reduce production. * **Muscarinic M2 receptor:** While M3 receptors are the primary targets in the eye (causing miosis and contraction of the ciliary muscle to increase trabecular outflow), M2 receptors are not the primary mediators for reducing aqueous secretion. **High-Yield Clinical Pearls for NEET-PG:** * **Brimonidine:** A highly selective $\alpha_2$ agonist. Key side effect: **Lid retraction** and **follicular conjunctivitis**. It is contraindicated in infants due to the risk of CNS depression/apnea. * **Apraclonidine:** Used primarily to prevent IOP spikes after laser procedures (e.g., YAG capsulotomy). * **Mechanism Summary:** * $\alpha_2$ Agonists: $\downarrow$ Production + $\uparrow$ Uveoscleral outflow. * $\beta$-Blockers: $\downarrow$ Production (only). * Prostaglandin Analogs (Latanoprost): $\uparrow$ Uveoscleral outflow (Most potent).
Explanation: **Explanation:** **Natamycin (Option B)** is the drug of choice for the topical treatment of filamentous fungal keratitis (keratomycosis). It is a polyene antifungal that acts by binding to fungal cell membrane ergosterols, leading to cell lysis. It is particularly effective against common causative organisms like *Fusarium* and *Aspergillus*. Its high efficacy and safety profile make it the only FDA-approved topical ophthalmic antifungal. **Analysis of Incorrect Options:** * **Silver sulfadiazine (Option A):** While it possesses some antifungal properties and was historically used, it is primarily an antibacterial agent used for burns. It is not the first-line choice for keratomycosis. * **Ketoconazole (Option C):** This is an imidazole antifungal. While it can be used orally for deep-seated fungal infections, its topical penetration through the corneal epithelium is inferior to Natamycin for superficial keratomycosis. * **Flucytosine (Option D):** This is an antimetabolite antifungal usually used in combination with Amphotericin B for systemic infections (like Cryptococcal meningitis). It is not used as a monotherapy or primary topical agent for fungal ulcers. **Clinical Pearls for NEET-PG:** * **Filamentous Fungi (*Fusarium*, *Aspergillus*):** Natamycin 5% is the gold standard. * **Yeasts (*Candida*):** Topical **Amphotericin B (0.15%)** is often preferred over Natamycin. * **Clinical Sign:** Fungal ulcers typically present with "feathery borders," "satellite lesions," and a "dry-looking" base. * **Contraindication:** Avoid topical steroids in suspected fungal keratitis as they worsen the infection. * **Deep Infections:** If the infection involves deep stroma, oral Voriconazole or Ketoconazole may be added to the regimen.
Ocular Pharmacokinetics
Practice Questions
Anti-infective Agents
Practice Questions
Anti-inflammatory Drugs
Practice Questions
Antiglaucoma Medications
Practice Questions
Mydriatics and Cycloplegics
Practice Questions
Ocular Lubricants
Practice Questions
Anti-VEGF Agents
Practice Questions
Ocular Diagnostic Agents
Practice Questions
Anesthetics in Ophthalmology
Practice Questions
Preservatives and Their Effects
Practice Questions
Ocular Toxicology
Practice Questions
Novel Drug Delivery Systems
Practice Questions
Get full access to all questions, explanations, and performance tracking.
Start For Free